Kathy Ordoñez is the Chief Executive Officer and Chairman of the Board of Directors at RainDance Technologies. Ms. Ordoñez became a member of the Board of Directors in July 2014, Chairman of the Board in September 2015 and Chief Executive Officer in June 2016. She brings more than 30 years of experience in the life sciences and diagnostics industries. Previously, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics where she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading provider of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann-La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.
Michael Hunkapiller, Ph.D. joined Alloy in 2004 after 21 years at Applied Biosystems (NYSE: ABI), which he helped grow from startup to almost $2 billion in annual revenues supplying instrument and reagent systems for life science research. At ABI, he held several positions, most recently as President and General Manager. Mr. Hunkapiller was also a founder of ABI’s sister company Celera Genomics (NYSE: CRA) and Senior Vice President of Applera Corporation (their parent company). Prior to joining ABI, he was a senior research fellow in the Division of Biology at the California Institute of Technology. Mr. Hunkapiller received a B.S. in chemistry from Oklahoma Baptist University in 1970 and a Ph.D. in chemical biology from the Division of Chemistry and Chemical Engineering at Caltech in 1974. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents, and has served on the editorial boards of several scientific journals. Mr. Hunkapiller has received several awards for his contributions to life science research, including the development of the automated DNA sequencing systems used to sequence the human genome. He is currently on the board of directors of NuGEN, Fluidigm, and Pacific Biosciences.
Phyllis Whiteley, Ph.D., a Venture Partner with Mohr Davidow Ventures has built a career founded on her passion for personalized medicine, global healthcare, and transformative life science innovations. She brings more than 25 years of experience across academics, biotech, and pharma in R&D, business, and portfolio management and has significant international experience, having established affiliates in Japan and Europe. Her work in pharmacology, immunology, and inflammation has resulted in multiple new chemical entities and publications. Dr. Whiteley is a Global Social Benefit Incubator (GSBI) mentor at Santa Clara University in Santa Clara, California. She received her B.A. in Chemistry and Ph.D. in Pharmacology from Washington University in St. Louis, Missouri.
P. Sherrill Neff is a founding partner of Quaker Partners, a $700 million Mid-Atlantic life sciences venture capital firm. Prior to forming Quaker Partners, he was President and Chief Operating Officer of Neose Technologies, Inc., a publicly traded life sciences company. Mr. Neff also previously served as Senior Vice President, Corporate Development at U.S. Healthcare, Inc., a leading publicly traded health maintenance organization. Mr. Neff was formerly a Managing Director in the investment banking division of Alex. Brown & Sons, and formerly an attorney at Morgan, Lewis & Bockius. Mr. Neff is a member of the Board of Directors of the National Venture Capital Association (NVCA), Resource Capital Corporation (NYSE:RSO), Biotechnology Institute, the Policy Board of WXPN. He also sits on the Boards of Biolex Therapeutics, Neuronetics, and Regado Biosciences. Mr. Neff is a graduate of Wesleyan University and the University of Michigan Law School.
Jeff Samberg is the Managing Member of Acadia Woods Partners, LLC, a New York-based investment partnership that focuses primarily on early-stage technology companies. He lived in the San Francisco Bay area for 15 years where he held a number of high-technology management roles, including Vice President of Corporate Strategy for PeopleSoft Inc., Vice President of Business Development for Wily Technology, and Entrepreneur in Residence for Greylock Partners. Mr. Samberg received his MBA from Stanford University’s Graduate School of Business and his B.A. with high honors in economics from Princeton University.
Martin M. Coyne II currently serves as a director of Akamai, a role he has held since November 2001. Before his retirement from Eastman Kodak in July 2003, he served in a variety of senior management positions including President of Health Imaging, President of the Commercial Business Group and most recently, Executive Vice President of Eastman Kodak and Group Executive of the Photography Group. Mr. Coyne also serves as Chairman of the Board of RockTech, a privately held SaaS business. He is President and CEO of the New Jersey Chapter of the National Association of Corporate Directors. In the past, he served as a director of BioClinica, OpenPages, Avecia Group Plc, director and Chairman of Welch Allyn and as a member of the board of AdvaMed. He is the author of a book and many articles on board governance, CEO leadership and improving CEO performance. He is also the Chairman and Founder of the CEO Learning Network.
Glenn P. Muir has extensive experience in financial management having guided Hologic from its early days with less than $10 million in revenue to its current position as one of the largest life science companies with annual revenues of over $2 billion. He was Hologic’s Chief Financial Officer from 1992 to May 2014 and Executive Vice President since 2000 with a broad range of financial and operating responsibilities including the oversight of the company’s strategic initiatives. Mr. Muir was at the helm for Hologic’s IPO in 1990. Currently the Audit Committee Chair at ReWalk Robotics Ltd, his Board of Director experience also includes Hologic, Inc. from 2001 to 2013 and Vivid Technologies, Inc. from 1996 until the company was sold to EG&G in 1999. He was named one of America’s Best CFOs by Institutional Investor in 2009 and CFO of the year by Boston Business Journals in 2011.
Bill Ericson leads investments in life sciences and software for Mohr Davidow Ventures (MDV). He works closely with a cross-discipline team of leading scientists, researchers, and entrepreneurs applying technology solutions to life sciences and health care in non-traditional ways. Mr. Ericson joined MDV after spending 10 years working with and investing in entrepreneurs and early-stage companies. During that time, he served as a board member of a number of life sciences and software companies, both public and private. Mr. Ericson was a member of the founding team of Rosetta Inpharmatics and served on the Board of Directors until its acquisition by Merck in 2001. He serves on the Board of Northwestern University School of Law and is a member of the Personalized Medicine Coalition. Mr. Ericson received his B.S.F.S. from Georgetown University of Foreign Service and J.D. from Northwestern University School of Law.
Alex de Winter is a director at GE Ventures, where he invests in life science instrumentation and clinical diagnostics. Alex joined GE Ventures from Mohr Davidow Ventures, where he served as a board director of On-Q-ity and board observer for CardioDx, Corventis, Crescendo Bioscience, DVS Sciences, and Personalis. He started his career as a research scientist with 454 Life Sciences and Pacific Biosciences. Alex has an MBA from UC Berkeley, a Ph.D. in Chemistry from Stanford, and graduated magna cum laude from Amherst College with a BA in English and Chemistry.